Kay A Ramsay1, Harpreet Sandhu2, James B Geake3, Emma Ballard4, Peter O'Rourke5, Claire E Wainwright6, David W Reid7, Timothy J Kidd8, Scott C Bell9. 1. Lung Bacteria Group, QIMR Berghofer Medical Research Institute, Herston Rd, Herston, Brisbane, Australia; School of Medicine, The University of Queensland, Herston Rd, Herston, Brisbane, Australia. Electronic address: kay.ramsay@qimrberghofer.edu.au. 2. Severn Postgraduate Medical Education (PGME) School of Primary Care, Office of General Practice, The Academy, Great Western Hospital, Marlborough Road, Swindon, United Kingdom. Electronic address: harps.k.sandhu@gmail.com. 3. Department of Thoracic Medicine, Royal Adelaide Hospital, North Tce, Adelaide, Australia; Respiratory Medicine, Lyell McEwin Hospital, Haydown Rd, Elizabeth Vale, Adelaide, Australia. Electronic address: James.Geake@sa.gov.au. 4. Statistics Unit, QIMR Berghofer Medical Research Institute, Herston Rd, Herston, Brisbane, Australia. Electronic address: Emma.Ballard@qimrberghofer.edu.au. 5. Statistics Unit, QIMR Berghofer Medical Research Institute, Herston Rd, Herston, Brisbane, Australia. Electronic address: Peter.O'Rourke@qimrberghofer.edu.au. 6. School of Medicine, The University of Queensland, Herston Rd, Herston, Brisbane, Australia; Lady Cilento Children's Hospital, Stanley St, South Brisbane, Australia. Electronic address: Claire.Wainwright@health.qld.gov.au. 7. Lung Inflammation and Infection Group, QIMR Berghofer Medical Research Institute, Herston Rd, Herston, Brisbane, Australia; Department of Thoracic Medicine, The Prince Charles Hospital, Rode Rd, Chermside, Brisbane, Australia. Electronic address: David.Reid@qimrberghofer.edu.au. 8. School of Chemistry and Molecular Biosciences, The University of Queensland, Cooper Rd, Brisbane, Australia; Centre for Experimental Medicine, Queen's University Belfast, University Rd, Belfast, United Kingdom; Child Health Research Centre, The University of Queensland, Graham St, South Brisbane, Australia. Electronic address: t.m.kidd@uq.edu.au. 9. Lung Bacteria Group, QIMR Berghofer Medical Research Institute, Herston Rd, Herston, Brisbane, Australia; School of Medicine, The University of Queensland, Herston Rd, Herston, Brisbane, Australia; Department of Thoracic Medicine, The Prince Charles Hospital, Rode Rd, Chermside, Brisbane, Australia. Electronic address: Scott.Bell@qimrbeghofer.edu.au.
Abstract
BACKGROUND: Increased patient longevity and aggressive antibiotic treatment are thought to impact on the microbial composition of the airways of adults with cystic fibrosis (CF). In this study, we sought to determine if a temporal change in the airway microbiology of adults with CF has occurred over time. METHODS: Longitudinal analysis of sputum microbiology results was undertaken on patients attending a large adult CF centre. Clinical status and health outcomes of transitioning patients were also assessed. RESULTS: A decrease in the prevalence of Pseudomonas aeruginosa, Staphylococcus aureus, Burkholderia cepacia complex and Aspergillus spp. (p=0.001, p<0.001, p=0.002 and p<0.001, respectively) occurred. Improvements in lung function among transitioning patients infected with P. aeruginosa were observed. CONCLUSION: Overtime, a decline in the prevalence of many CF airway pathogens has occurred. Significantly, an incremental improvement in lung function was reported for transitioning patients with current P. aeruginosa infections.
BACKGROUND: Increased patient longevity and aggressive antibiotic treatment are thought to impact on the microbial composition of the airways of adults with cystic fibrosis (CF). In this study, we sought to determine if a temporal change in the airway microbiology of adults with CF has occurred over time. METHODS: Longitudinal analysis of sputum microbiology results was undertaken on patients attending a large adult CF centre. Clinical status and health outcomes of transitioning patients were also assessed. RESULTS: A decrease in the prevalence of Pseudomonas aeruginosa, Staphylococcus aureus, Burkholderia cepacia complex and Aspergillus spp. (p=0.001, p<0.001, p=0.002 and p<0.001, respectively) occurred. Improvements in lung function among transitioning patients infected with P. aeruginosa were observed. CONCLUSION: Overtime, a decline in the prevalence of many CF airway pathogens has occurred. Significantly, an incremental improvement in lung function was reported for transitioning patients with current P. aeruginosa infections.
Authors: B D Edwards; J Greysson-Wong; R Somayaji; B Waddell; F J Whelan; D G Storey; H R Rabin; M G Surette; M D Parkins Journal: J Clin Microbiol Date: 2017-04-26 Impact factor: 5.948
Authors: Matthew R Crull; Ranjani Somayaji; Kathleen J Ramos; Ellen Caldwell; Nicole Mayer-Hamblett; Moira L Aitken; David P Nichols; Ali Rowhani-Rahbar; Christopher H Goss Journal: Clin Infect Dis Date: 2018-09-14 Impact factor: 9.079
Authors: Anna S Tai; Laura J Sherrard; Timothy J Kidd; Kay A Ramsay; Cameron Buckley; Melanie Syrmis; Keith Grimwood; Scott C Bell; David M Whiley Journal: BMC Pulm Med Date: 2017-11-02 Impact factor: 3.317
Authors: Peter H Gilligan; Damian G Downey; J Stuart Elborn; Patrick A Flume; Sebastian Funk; Deirdre Gilpin; Timothy J Kidd; John McCaughan; B Cherie Millar; Philip G Murphy; Jacqueline C Rendall; Michael M Tunney; John E Moore Journal: J Clin Microbiol Date: 2018-08-27 Impact factor: 5.948
Authors: Bryan A Wee; Anna S Tai; Laura J Sherrard; Nouri L Ben Zakour; Kirt R Hanks; Timothy J Kidd; Kay A Ramsay; Iain Lamont; David M Whiley; Scott C Bell; Scott A Beatson Journal: BMC Genomics Date: 2018-08-30 Impact factor: 3.969
Authors: Champa N Ratnatunga; Viviana P Lutzky; Andreas Kupz; Denise L Doolan; David W Reid; Matthew Field; Scott C Bell; Rachel M Thomson; John J Miles Journal: Front Immunol Date: 2020-03-03 Impact factor: 7.561